Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Prima BioMed Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Prima BioMed Enters into Agreement with Cytlimic 11
WuXi Biologics to Partner with Prima Biomed 12
Prima BioMed to Enter into Agreement with Krankenhaus Nordwest 13
Immutep Enters Into Development Agreement With Eddingpharm For ImmuFact IMP321 14
Licensing Agreements 15
Sydys Enters into Licensing Agreement with Prima BioMed 15
Prima BioMed Enters Into Licensing Agreement With Neopharm For CVac 16
CoStim Pharma Enters into Licensing Agreement with Immutep 17
Immutep Enters Into Licensing Agreement With GlaxoSmithKline For ImmuTune IMP731 18
Equity Offering 19
Prima BioMed Plans Public Offering of American Depository Shares 19
Prima BioMed Raises USD5 Million in Private Placement of ADSs 20
Prima BioMed Raises USD1.4 Million in Private Placement of Shares 22
Prima BioMed Raises USD1.14 Million in Private Placement of Shares 23
Prima BioMed Raises USD7.5 Million in Rights Offering of Shares 24
Prima BioMed Raises USD0.19 Million in Private Placement of Shares upon Exercise of Warrants 25
Prima BioMed Plans to Raise USD4 Million in Rights Offering of Shares 26
Prima BioMed to Raise USD1 Million in Private Placement of Shares 27
Prima BioMed Files Registration Statement For Public Offering Of American Depositary Shares For US$60 Million 28
Prima BioMed Completes Second Tranche Of Private Placement Of Shares For US$3 Million 29
Prima BioMed Completes Private Placement Of Shares For US$1.3 Million 30
Prima BioMed Completes Private Placement Of Shares For US$1 Million 31
Prima BioMed Completes Rights Offering Of Shares For US$5.2 Million 32
Prima BioMed Completes Rights Issue Of US$21 Million 33
Prima BioMed Completes Private Placement Of US$22 Million 34
Debt Offering 35
Prima BioMed to Raise USD11 Million in Private Placement of 3% Notes 35
Acquisition 36
Prima BioMed Acquires Immutep for USD25 Million 36
Prima BioMed Ltd – Key Competitors 37
Prima BioMed Ltd – Key Employees 38
Prima BioMed Ltd – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Corporate Communications 40
Aug 20, 2017: Prima BioMed Appoints Non-Executive Director to the Board 40
Government and Public Interest 41
Aug 30, 2017: Prima Biomed And Monash University Receive Funding Grant For Lag-3 Research Project 41
Aug 16, 2017: Prima Biomed Receives A$1.3 Million Tax Refund From French Government 42
Product News 43
10/17/2017: IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer 2017 Annual Meeting 43
10/12/2016: Prima to Present at 2016 Society for Immunotherapy of Cancer Conference 44
10/06/2016: Prima Abstracts Accepted for Poster Presentation at ESMO Symposium on Immuno-Oncology 45
08/16/2017: Prima BioMed Receives A $1.3 Million Tax Refund From French Government 46
07/09/2017: Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial 47
06/04/2017: LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial 48
06/01/2017: Prima Biomed Announces Formation Of Clinical Advisory Board 49
03/15/2017: Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston 50
03/15/2016: IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal 51
02/24/2017: First Half 2017 Operational Update 52
01/03/2017: Prima Announces New Product Candidate IMP761 – A LAG-3 Agonist Antibody 53
Clinical Trials 54
Oct 31, 2017: Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017 54
Oct 19, 2017: Dr. Frederic Triebel Presenting at the World Immunotherapy Congress 2017 55
Jun 26, 2017: Prima BioMed provides clinical trial update on IMP321 56
May 17, 2017: Data From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference 57
Apr 19, 2017: Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial 58
Apr 12, 2017: Prima BioMed receives A$492,144 Tax Refund from Australian Government 59
Jan 23, 2017: Prima Biomed To Present At 2nd Annual Cancer Immunotherapy Conference 60
Jan 20, 2017: Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer 61
Jan 12, 2017: Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial 62
Dec 29, 2016: Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1 63
Dec 22, 2016: Prima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer 64
Dec 20, 2016: Prima BioMed Receives UK Approval for AIPAC Study 65
Jul 12, 2016: Prima BioMed Collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors 66
Jun 22, 2016: Prima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321 67
Mar 02, 2016: Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial 68
Jan 26, 2016: Prima BioMed Initiates Phase I Melanoma Study in Australia 69
Other Significant Developments 71
Nov 20, 2017: Change of company name from Prima BioMed Limited‘ to Immutep 71
Nov 20, 2017: Prima BioMed Changes its Name to Immutep 72
Aug 18, 2016: Prima BioMed: Operational Update 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Prima BioMed Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Prima BioMed Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Prima BioMed Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Prima BioMed Enters into Agreement with Cytlimic 11
WuXi Biologics to Partner with Prima Biomed 12
Prima BioMed to Enter into Agreement with Krankenhaus Nordwest 13
Immutep Enters Into Development Agreement With Eddingpharm For ImmuFact IMP321 14
Sydys Enters into Licensing Agreement with Prima BioMed 15
Prima BioMed Enters Into Licensing Agreement With Neopharm For CVac 16
CoStim Pharma Enters into Licensing Agreement with Immutep 17
Immutep Enters Into Licensing Agreement With GlaxoSmithKline For ImmuTune IMP731 18
Prima BioMed Plans Public Offering of American Depository Shares 19
Prima BioMed Raises USD5 Million in Private Placement of ADSs 20
Prima BioMed Raises USD1.4 Million in Private Placement of Shares 22
Prima BioMed Raises USD1.14 Million in Private Placement of Shares 23
Prima BioMed Raises USD7.5 Million in Rights Offering of Shares 24
Prima BioMed Raises USD0.19 Million in Private Placement of Shares upon Exercise of Warrants 25
Prima BioMed Plans to Raise USD4 Million in Rights Offering of Shares 26
Prima BioMed to Raise USD1 Million in Private Placement of Shares 27
Prima BioMed Files Registration Statement For Public Offering Of American Depositary Shares For US$60 Million 28
Prima BioMed Completes Second Tranche Of Private Placement Of Shares For US$3 Million 29
Prima BioMed Completes Private Placement Of Shares For US$1.3 Million 30
Prima BioMed Completes Private Placement Of Shares For US$1 Million 31
Prima BioMed Completes Rights Offering Of Shares For US$5.2 Million 32
Prima BioMed Completes Rights Issue Of US$21 Million 33
Prima BioMed Completes Private Placement Of US$22 Million 34
Prima BioMed to Raise USD11 Million in Private Placement of 3% Notes 35
Prima BioMed Acquires Immutep for USD25 Million 36
Prima BioMed Ltd, Key Competitors 37
Prima BioMed Ltd, Key Employees 38
Prima BioMed Ltd, Subsidiaries 39
